Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety

U. A. Matulonis; R. T. Penson; S. M. Domchek; B. Kaufman; R. Shapira-Frommer; M. W. Audeh; S. Kaye; L. R. Molife; K. A. Gelmon; J. D. Robertson; H. Mann; T. W. Ho; R. L. Coleman

doi:10.1093/annonc/mdw133

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety

U. A. Matulonis, R. T. Penson, S. M. Domchek, B. Kaufman, R. Shapira-Frommer, M. W. Audeh, S. Kaye, L. R. Molife, K. A. Gelmon, J. D. Robertson, H. Mann, T. W. Ho, R. L. Coleman

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The PARP inhibitor olaparib (Lynparza™) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data from olaparib monotherapy trials were used to explore the treatment effect of olaparib in patients with gBRCAm ovarian cancer who had received multiple lines of prior chemotherapy.

Original language	English
Pages (from-to)	1013-1019
Number of pages	7
Journal	Annals of Oncology
Volume	27
Issue number	6
DOIs	https://doi.org/10.1093/annonc/mdw133
State	Published - 18 Jun 2016
Externally published	Yes

Keywords

BRCA1/2 mutation
monotherapy
olaparib
ovarian cancer
pooled analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdw133

Cite this

Matulonis, U. A., Penson, R. T., Domchek, S. M., Kaufman, B., Shapira-Frommer, R., Audeh, M. W., Kaye, S., Molife, L. R., Gelmon, K. A., Robertson, J. D., Mann, H., Ho, T. W., & Coleman, R. L. (2016). Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety. Annals of Oncology, 27(6), 1013-1019. https://doi.org/10.1093/annonc/mdw133

Matulonis, U. A. ; Penson, R. T. ; Domchek, S. M. ; Kaufman, B. ; Shapira-Frommer, R. ; Audeh, M. W. ; Kaye, S. ; Molife, L. R. ; Gelmon, K. A. ; Robertson, J. D. ; Mann, H. ; Ho, T. W. ; Coleman, R. L. / Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation : A multistudy analysis of response rates and safety. In: Annals of Oncology. 2016 ; Vol. 27, No. 6. pp. 1013-1019.

@article{7bfbc4a2b12046529895d292dbb7a470,

title = "Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety",

abstract = "Background: The PARP inhibitor olaparib (Lynparza{\texttrademark}) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data from olaparib monotherapy trials were used to explore the treatment effect of olaparib in patients with gBRCAm ovarian cancer who had received multiple lines of prior chemotherapy.",

keywords = "BRCA1/2 mutation, monotherapy, olaparib, ovarian cancer, pooled analysis",

author = "Matulonis, {U. A.} and Penson, {R. T.} and Domchek, {S. M.} and B. Kaufman and R. Shapira-Frommer and Audeh, {M. W.} and S. Kaye and Molife, {L. R.} and Gelmon, {K. A.} and Robertson, {J. D.} and H. Mann and Ho, {T. W.} and Coleman, {R. L.}",

note = "Publisher Copyright: {\textcopyright} The Author 2016.",

year = "2016",

month = jun,

day = "18",

doi = "10.1093/annonc/mdw133",

language = "אנגלית",

volume = "27",

pages = "1013--1019",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "6",

}

Matulonis, UA, Penson, RT, Domchek, SM, Kaufman, B, Shapira-Frommer, R, Audeh, MW, Kaye, S, Molife, LR, Gelmon, KA, Robertson, JD, Mann, H, Ho, TW & Coleman, RL 2016, 'Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety', Annals of Oncology, vol. 27, no. 6, pp. 1013-1019. https://doi.org/10.1093/annonc/mdw133

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation : A multistudy analysis of response rates and safety. / Matulonis, U. A.; Penson, R. T.; Domchek, S. M.; Kaufman, B.; Shapira-Frommer, R.; Audeh, M. W.; Kaye, S.; Molife, L. R.; Gelmon, K. A.; Robertson, J. D.; Mann, H.; Ho, T. W.; Coleman, R. L.

In: Annals of Oncology, Vol. 27, No. 6, 18.06.2016, p. 1013-1019.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation

T2 - A multistudy analysis of response rates and safety

AU - Matulonis, U. A.

AU - Penson, R. T.

AU - Domchek, S. M.

AU - Kaufman, B.

AU - Shapira-Frommer, R.

AU - Audeh, M. W.

AU - Kaye, S.

AU - Molife, L. R.

AU - Gelmon, K. A.

AU - Robertson, J. D.

AU - Mann, H.

AU - Ho, T. W.

AU - Coleman, R. L.

PY - 2016/6/18

Y1 - 2016/6/18

N2 - Background: The PARP inhibitor olaparib (Lynparza™) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data from olaparib monotherapy trials were used to explore the treatment effect of olaparib in patients with gBRCAm ovarian cancer who had received multiple lines of prior chemotherapy.

AB - Background: The PARP inhibitor olaparib (Lynparza™) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data from olaparib monotherapy trials were used to explore the treatment effect of olaparib in patients with gBRCAm ovarian cancer who had received multiple lines of prior chemotherapy.

KW - BRCA1/2 mutation

KW - monotherapy

KW - olaparib

KW - ovarian cancer

KW - pooled analysis

UR - http://www.scopus.com/inward/record.url?scp=84974803101&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw133

DO - 10.1093/annonc/mdw133

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 26961146

AN - SCOPUS:84974803101

VL - 27

SP - 1013

EP - 1019

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this